UK approves Pfizer bivalent Covid vaccine ahead of booster drive
The UK regulator last month okayed a similar bivalent vaccine by Moderna, becoming the first country to do so
LONDON: The UK's drug regulator said Saturday it had approved an updated Covid-19 jab by Pfizer/BioNTEch targeting the original virus and a subvariant ahead of an autumn booster drive.
The so-called "bivalent" jabs work for both the original virus that emerged in the Chinese city of Wuhan in 2019 and the BA.1 subvariant of Omicron.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved the Pfizer jab as a booster for those aged 12 and over after a "careful review of the evidence".
The UK regulator last month okayed a similar bivalent vaccine by Moderna, becoming the first country to do so.
MHRA chief executive June Raine said: "I am pleased to announce that we now have a second approved vaccine for the UK Autumn booster programme."
The National Health Service in England and Scotland will begin a fresh booster rollout on Monday, starting with care home residents and eventually inviting everyone over 50.
The other UK regions of Wales and Northern Ireland are also launching similar campaigns.
The BBC reported Saturday that the Moderna bivalent shot would be offered first, but added that the UK did not have enough supplies to cover everyone over 50.
The European Union and the United States have recently authorised the updated version of the Pfizer vaccine and Moderna vaccines.
-
Is ‘Fibremaxxing’ really improving your gut health? Scientists reveal truth
-
Is teen anger linked to faster aging? Here’s what the study reveals
-
Teddi Mellencamp reveals medication side-effects landed her in the hospital
-
Billy Porter claims he came back from the dead amid sepsis battle
-
Childhood obesity crisis: 220 million kids may be affected by 2040, report warns
-
Christopher Reid gives update on his ‘heart failure’
-
Paris Hilton's power move to make 'neurodiversity relatable'
-
GLP-1 drugs linked to osteoporosis and gout: New study reveals higher risks